Tenaya Therapeutics Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Tenaya Therapeutics Inc Company

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.

Tenaya Therapeutics Inc Info



Ticker SymbolTNYA

Company nameTenaya Therapeutics Inc

IPO dateJul 30, 2021

CEOMr. Faraz Ali

Number of employees97

Security typeOrdinary Share

Fiscal year-endJul 30

Address171 Oyster Point Blvd., Suite 500

CitySOUTH SAN FRANCISCO

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code94080

Phone14158652066

Websitehttps://www.tenayatherapeutics.com/

Ticker SymbolTNYA

IPO dateJul 30, 2021

CEOMr. Faraz Ali

Company Executives of Tenaya Therapeutics Inc



Name

Name/Position

Position

Shareholding

Change

Mr. Faraz Ali

Chief Executive Officer, Director

82.91K

-14.91%

Dr. Catherine Stehman-Breen, M.D.

Independent Director

8.13K

--

Dr. Whittemore (Whit) Tingley, M.D., Ph.D.

Chief Medical Officer

--

Ms. Karah Parschauer, J.D.

Independent Director

--

Dr. R. Sanders (Sandy) Williams, M.D.

Independent Chairman of the Board

--

Ms. Amy L. Burroughs

Independent Director

--

Dr. June Lee, M.D.

Independent Director

--

Dr. David V. Goeddel, Ph.D.

Independent Director

--

Mr. Jeffrey T. (Jeff) Walsh

Independent Director

--

Dr. Deepak Srivastava, M.D.

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Mr. Faraz Ali

Chief Executive Officer, Director

82.91K

-14.91%

Dr. Catherine Stehman-Breen, M.D.

Independent Director

8.13K

--

Dr. Whittemore (Whit) Tingley, M.D., Ph.D.

Chief Medical Officer

--

Ms. Karah Parschauer, J.D.

Independent Director

--

Dr. R. Sanders (Sandy) Williams, M.D.

Independent Chairman of the Board

--

Ms. Amy L. Burroughs

Independent Director

--

Revenue Breakdown

No Data

No Data

By Business

By Region

No Data

Shareholding Stats

Updated: Sat, Aug 23

Shareholders

Shareholder Types

Shareholders

Proportion

The Column Group LP

5.77%

The Vanguard Group, Inc.

2.92%

Empery Asset Management, L.P.

2.89%

BlackRock Institutional Trust Company, N.A.

1.64%

Renaissance Technologies LLC

1.13%

Other

85.66%

Shareholders

Proportion

The Column Group LP

5.77%

The Vanguard Group, Inc.

2.92%

Empery Asset Management, L.P.

2.89%

BlackRock Institutional Trust Company, N.A.

1.64%

Renaissance Technologies LLC

1.13%

Other

85.66%

Shareholder Types

Shareholders

Proportion

Investment Advisor

6.48%

Venture Capital

6.33%

Investment Advisor/Hedge Fund

5.83%

Hedge Fund

2.39%

Individual Investor

0.70%

Research Firm

0.55%

Private Equity

0.28%

Family Office

0.18%

Other

77.25%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

228

35.64M

21.87%

-78.22M

2025Q2

235

93.48M

57.36%

+20.23M

2025Q1

240

59.62M

37.68%

-6.11M

2024Q4

227

46.66M

58.78%

-21.29M

2024Q3

228

59.37M

75.30%

-7.13M

2024Q2

219

58.72M

74.83%

-7.58M

2024Q1

206

57.55M

73.35%

-12.34M

2023Q4

191

47.88M

70.30%

-10.62M

2023Q3

197

52.92M

79.61%

-6.27M

2023Q2

192

50.82M

77.84%

-5.65M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

The Column Group LP

9.40M

5.77%

-39.91M

-80.94%

Jun 30, 2025

The Vanguard Group, Inc.

4.76M

2.92%

+673.29K

+16.49%

Jun 30, 2025

Empery Asset Management, L.P.

4.71M

2.89%

-4.02M

-46.09%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

2.67M

1.64%

-2.29M

-46.20%

Jun 30, 2025

Renaissance Technologies LLC

1.84M

1.13%

+302.15K

+19.60%

Jun 30, 2025

AQR Capital Management, LLC

1.74M

1.07%

+966.57K

+124.61%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.23M

0.76%

-144.59K

-10.51%

Jun 30, 2025

Euclidean Capital, L.L.C.

1.02M

0.62%

--

Jun 30, 2025

Alphabet, Inc.

915.71K

0.56%

--

Jun 30, 2025

Millennium Management LLC

680.74K

0.42%

+638.69K

+1518.89%

Jun 30, 2025

Related ETFs



Updated: Thu, Nov 6

Name

Proportion

iShares Russell 2000 ETF

0%

Fidelity Enhanced Small Cap ETF

0%

Tema Heart & Health ETF

0%

iShares Health Innovation Active ETF

0%

ProShares Hedge Replication ETF

0%

Global X Russell 2000 Covered Call ETF

0%

iShares Micro-Cap ETF

0%

iShares Russell 2000 Value ETF

0%

iShares Russell 2000 Growth ETF

0%

iShares Russell 3000 ETF

0%

iShares Russell 2000 ETF

Proportion0%

Fidelity Enhanced Small Cap ETF

Proportion0%

Tema Heart & Health ETF

Proportion0%

iShares Health Innovation Active ETF

Proportion0%

ProShares Hedge Replication ETF

Proportion0%

Global X Russell 2000 Covered Call ETF

Proportion0%

iShares Micro-Cap ETF

Proportion0%

iShares Russell 2000 Value ETF

Proportion0%

iShares Russell 2000 Growth ETF

Proportion0%

iShares Russell 3000 ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data